Compare Caesars Entertainment Inc (CZR) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Caesars Entertainment Inc vs BIO-TECHNE Corp — how do they compare? Caesars Entertainment Inc trades at $29.74 (market cap $6.13B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: BIO-TECHNE Corp is the larger of the two by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Caesars Entertainment Inc pays none. Which is the better fit depends on your goals.
| CZR | TECH | |
|---|---|---|
Market Cap | $6.13B | $11.24B |
Sector | Consumer Cyclical | Health |
52-Week High | $30.41 | $72.29 |
52-Week Low | $18.14 | $43.31 |
Enterprise Value | $30.02B | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Caesars Entertainment (CZR) trades at $30.15, up 0.33% with a bullish technical signal despite recent earnings misses. The company reported Q2 2026 revenue of $3.0 billion but a $0.30 per share loss, missing expectations. Valuation metrics appear attractive with P/E of 10.42 and P/S of 0.53, though profitability remains challenged with negative net margins. The pending $5.7 billion acquisition by Tilman Fertitta provides strategic uncertainty while recent property openings and online expansion signal growth initiatives.
CZR presents a mixed investment case with reasonable valuation offset by persistent profitability challenges. The acquisition premium offers near-term upside potential, but execution risks and competitive pressures in the gaming sector warrant caution. Analyst sentiment leans cautious with 70% hold ratings, reflecting uncertainty around the merger outcome and operational turnaround prospects.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Caesars Entertainment Inc
Caesars Entertainment includes around 50 domestic gaming properties across Las Vegas (50% of 2021 EBITDAR before corporate and digital expenses) and regional (63%) markets. Additionally, the company hosts managed properties and digital assets, the later of which produced material EBITDA losses in 2021. Caesars' U.S. presence roughly doubled with the 2020 acquisition by Eldorado, which built its first casino in Reno, Nevada, in 1973 and expanded its presence through prior acquisitions to over 20 properties before merging with legacy Caesars. Caesars' brands include Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo. Also, the company owns the U.S. portion of William Hill (it plans to sell the international operation in 2022), a digital sports betting platform.
Read more on CZR →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
